Clinical Trial Update: The Use of Blinatumomab in Patients With NGS-MRD Relapsed B-ALL After Autologous/Allogeneic Transplantation [NA]

View source ↗

Summary

Clinical trial evaluating blinatumomab for patients with NGS-MRD positive relapsed B-cell acute lymphoblastic leukemia after autologous or allogeneic transplant…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• B-cell Acute Lymphoblastic Leukemia

Drugs mentioned

• BLINCYTO (BLINATUMOMAB)

Snippet

Sponsor: Institute of Hematology & Blood Diseases Hospital, China | Conditions: B-ALL | NA | Status: NOT_YET_RECRUITING